Literature DB >> 18308560

Advances in understanding L-DOPA-induced dyskinesia.

M A Cenci1, H S Lindgren.   

Abstract

The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disorders caused by either a deficiency or a hyperactivity of dopaminergic transmission in the basal ganglia. The degeneration of nigrostriatal DA neurons in Parkinson's disease causes poverty and slowness of movement. These symptoms are greatly improved by pharmacological DA replacement with L-3,4-dihydroxy-phenylalanine (L-DOPA), which however causes excessive involuntary movements in a majority of patients. L-DOPA-induced dyskinesia (abnormal involuntary movements) provides a topic of investigation at the interface between clinical and basic neuroscience. In this article, we review recent studies in rodent models, which have uncovered two principal alterations at the basis of the movement disorder, namely, an abnormal pre-synaptic handling of exogenous L-DOPA, and a hyper-reactive post-synaptic response to DA. Dysregulated nigrostriatal DA transmission causes secondary alterations in a variety of non-dopaminergic transmitter systems, the manipulation of which modulates dyskinesia through mechanisms that are presently unclear. Further research on L-DOPA-induced dyskinesia will contribute to a deeper understanding of the functional interplay between neurotransmitters and neuromodulators in the motor circuits of the basal ganglia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308560     DOI: 10.1016/j.conb.2008.01.004

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  32 in total

1.  Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.

Authors:  K Elisabet Ohlin; Irene Sebastianutto; Chris E Adkins; Cornelia Lundblad; Paul R Lockman; M Angela Cenci
Journal:  Neuroimage       Date:  2012-03-03       Impact factor: 6.556

2.  Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.

Authors:  Tanya Chotibut; Samantha Meadows; Ella A Kasanga; Tamara McInnis; Mark A Cantu; Christopher Bishop; Michael F Salvatore
Journal:  Mov Disord       Date:  2017-06-20       Impact factor: 10.338

3.  Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.

Authors:  N Yamamoto; J-J Soghomonian
Journal:  Neuroscience       Date:  2009-08-04       Impact factor: 3.590

4.  Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.

Authors:  Tanuja Bordia; Xiomara A Perez; Jaime Heiss; Danhui Zhang; Maryka Quik
Journal:  Neurobiol Dis       Date:  2016-02-24       Impact factor: 5.996

5.  Aberrant CpG Methylation Mediates Abnormal Transcription of MAO-A Induced by Acute and Chronic L-3,4-Dihydroxyphenylalanine Administration in SH-SY5Y Neuronal Cells.

Authors:  Zhaofei Yang; Xuan Wang; Jian Yang; Min Sun; Yong Wang; Xiaomin Wang
Journal:  Neurotox Res       Date:  2016-12-15       Impact factor: 3.911

6.  The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Christopher Bishop; S Paul Berger; Melanie A Paquette
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

7.  α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.

Authors:  Maryka Quik; Carla Campos; Tanuja Bordia; Jon-Paul Strachan; Jenny Zhang; J Michael McIntosh; Sharon Letchworth; Kristen Jordan
Journal:  Neuropharmacology       Date:  2013-04-12       Impact factor: 5.250

8.  Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model.

Authors:  Tanya Chotibut; Richard W Davis; Jennifer C Arnold; Zachary Frenchek; Shawn Gurwara; Vimala Bondada; James W Geddes; Michael F Salvatore
Journal:  Mol Neurobiol       Date:  2013-12-03       Impact factor: 5.590

9.  PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking.

Authors:  Gregory Porras; Amandine Berthet; Benjamin Dehay; Qin Li; Laurent Ladepeche; Elisabeth Normand; Sandra Dovero; Audrey Martinez; Evelyne Doudnikoff; Marie-Laure Martin-Négrier; Qin Chuan; Bertrand Bloch; Daniel Choquet; Eric Boué-Grabot; Laurent Groc; Erwan Bezard
Journal:  J Clin Invest       Date:  2012-10-08       Impact factor: 14.808

10.  The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.

Authors:  Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2013-03-03       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.